cookie

We use cookies to improve your browsing experience. By clicking «Accept all», you agree to the use of cookies.

avatar

Dr. Lynn Fynn’s Science Enlightenment Channel & Stuff

Advertising posts
32 924
Subscribers
-724 hours
-487 days
-30330 days
Posting time distributions

Data loading in progress...

Find out who reads your channel

This graph will show you who besides your subscribers reads your channel and learn about other sources of traffic.
Views Sources
Publication analysis
PostsViews
Shares
Views dynamics
01
1300+ citations on reactivating p53- https://pubmed.ncbi.nlm.nih.gov/?term=reactivation+p53
2 61124Loading...
02
"There are 5137 cerebral thromboembolism AEs reported in [VAERS] the 3 years (36 months) after COVID-19 vaccines compared to 52 AEs for the influenza vaccines over the past 34 years (408 months) and 282 AEs for all other vaccines (excluding COVID-19) over the past 34 years (408 months). The PRR’s are significant when comparing AEs by time from COVID-19 vaccines to that of the influenza vaccines (p < 0.0001) or to that of all other vaccines (p < 0.0001)." https://www.preprints.org/manuscript/202406.1236/v1
7 051120Loading...
1300+ citations on reactivating p53- https://pubmed.ncbi.nlm.nih.gov/?term=reactivation+p53
Show all...
reactivation p53 - Search Results - PubMed

"There are 5137 cerebral thromboembolism AEs reported in [VAERS] the 3 years (36 months) after COVID-19 vaccines compared to 52 AEs for the influenza vaccines over the past 34 years (408 months) and 282 AEs for all other vaccines (excluding COVID-19) over the past 34 years (408 months). The PRR’s are significant when comparing AEs by time from COVID-19 vaccines to that of the influenza vaccines (p < 0.0001) or to that of all other vaccines (p < 0.0001)." https://www.preprints.org/manuscript/202406.1236/v1
Show all...
COVID-19 Vaccines: A Risk Factor for Cerebral Thrombotic Syndromes

Introduction: This population-based retrospective cohort study assesses rates of adverse events (AEs) involving cerebral thromboembolism (CTE) after COVID-19 vaccines. Methods: Data were collected from the U.S. Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) Vaccine Adverse Event Reporting System (VAERS) database from January 1, 1990 to December 31, 2023. CTE AEs after COVID-19 vaccines were compared to those after influenza vaccines and after all other vaccines using proportional reporting ratio (PRR) analysis by time. Results: There are 5137 cerebral thromboembolism AEs reported in the 3 years (36 months) after COVID-19 vaccines compared to 52 AEs for the influenza vaccines over the past 34 years (408 months) and 282 AEs for all other vaccines (excluding COVID-19) over the past 34 years (408 months). The PRR’s are significant when comparing AEs by time from COVID-19 vaccines to that of the influenza vaccines (p < 0.0001) or to that of all other vaccines (p < 0.0001).…

Go to the archive of posts
Choose a Different Plan

Your current plan allows analytics for only 5 channels. To get more, please choose a different plan.